Browse the evidence

Incretin-based therapies, including GLP-1 receptor agonists like semaglutide and tirzepatide, can improve quality of life, exercise tolerance, and markers of HF severity while promoting weight loss in patients with obesity and HFpEF.

Practitioners may consider incretin-based therapies as effective treatment options for improving health outcomes in patients with obesity-related HFpEF.

Semaglutide can be used safely and efficiently in non-diabetic people with excess weight.

Semaglutide may be considered as a treatment option for weight management in non-diabetic patients.

GLP-1 receptor agonists have demonstrated efficacy and safety in treating type 2 diabetes and obesity.

GLP-1 receptor agonists can be considered effective options for managing type 2 diabetes and obesity.

New pharmacologic advances in glucagon-like peptide-1 agonists, such as semaglutide, have shown promising effectiveness for weight management.

Plastic surgeons should consider the role of GLP-1 agonists in managing obesity in surgical patients.

Semaglutide and tirzepatide are effective medication options for obesity management.

Practitioners can consider semaglutide and tirzepatide as viable options for treating obesity.

Tirzepatide demonstrates unprecedented efficacy for glycaemic control, reductions in body weight, and improvements in blood pressure and lipid profile compared with placebo and GLP-1 receptor agonists.

Tirzepatide may be a highly effective treatment option for managing glycaemic control and weight in patients with T2D and obesity.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) help manage type 2 diabetes mellitus (T2DM) by controlling blood sugar and promoting weight loss.

GLP-1RAs can be considered as a treatment option for patients with T2DM who need to manage blood sugar and weight.

GLP-1 receptor agonists (GLP-1RAs) have transformed the management of obesity and provide unprecedented efficacy and acceptable safety in weight reduction and glycemic control.

Practitioners can consider GLP-1RAs as effective options for managing obesity and glycemic control in patients.

Glucagon-like peptide-1 (GLP-1) agonists lead to greater weight loss in clinical trials and real-world settings than orlistat.

GLP-1 agonists may be a more effective pharmacological option for weight management in patients with obesity and inflammatory skin conditions.

Tirzepatide effectively reduces glucose levels and body weight in patients with type 2 diabetes and/or obesity.

Clinicians can consider tirzepatide as a treatment option for managing glucose levels and weight in these patients.

Tirzepatide (TZP) offers superior efficacy in reducing glycemic levels and body weight compared to existing therapies.

Practitioners may consider TZP as a more effective treatment option for patients struggling to achieve glycemic control and weight loss.

GLP-1 medicines reduce food intake, body weight, insulin resistance and inflammation.

GLP-1 medicines can be considered for managing weight and metabolic health in patients with type 2 diabetes and obesity.

Incretin mimetics, including glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists, are first-line treatment options for type 2 diabetes and obesity.

Healthcare professionals should consider these agents as primary treatment options for managing type 2 diabetes and obesity.

Semaglutide demonstrated superior efficacy with mean HbA1c reduction of 1.45% and weight loss of 1.44 kg.

Semaglutide is the most effective GLP-1 receptor agonist for improving glycemic control and promoting weight loss in T2DM patients.

Emerging oral therapies could complement or serve as alternatives to approved injectable treatments for long-term weight management.

Practitioners should consider these oral therapies as viable options alongside injectables.

Preconception weight optimization in women with obesity is important to reduce maternal and fetal risks.

Practitioners should prioritize weight management in women with obesity planning for pregnancy.

Average A1c decreased from 8.9% ± 1.3% to 7.6% ± 1.5% over 6 months (P < 0.001).

Clinicians may expect improvements in glycemic control with semaglutide in T2DM patients.

Body weight decreased from 123.9 ± 23.5 kg to 118.9 ± 22.9 kg over 6 months (P < 0.001).

Clinicians may observe weight loss in T2DM patients treated with semaglutide.

Newer anti-obesity medications such as semaglutide and tirzepatide have shown greater than 15% reduction in baseline weight.

Practitioners should consider these medications for patients seeking significant weight loss.

GLP-1 agonists are associated with favorable hemoglobin A1C levels and weight loss in type 1 diabetic patients.

GLP-1 agonists may be recommended for type 1 diabetes patients aiming for better glycemic control and weight management.

Tirzepatide treatment shows a potent glucose-lowering effect and promotes weight loss with minimal GI adverse effects.

Tirzepatide may be considered for patients needing effective glucose control and weight loss with fewer gastrointestinal side effects.

Semaglutide had substantial effects on multiple secondary alcohol-related and somatic outcomes.

Semaglutide may improve various aspects of health related to alcohol use disorder in addition to reducing drinking.

Semaglutide resulted in a similar reduction in body weight across frailty subgroups.

Semaglutide can be used effectively for weight management in patients with obesity-related HFpEF, regardless of frailty status.

Semaglutide 2.4 mg reduces body weight by an estimated mean change ranging from -9.40% to -16.42% in an East Asian population.

Practitioners can consider semaglutide 2.4 mg as an effective option for weight loss in East Asian adults with obesity.